Medico Intercon.

Which are the latest news on Medico Intercon.?

Are Medico Intercontinental Ltd latest results good or bad?

Medico Intercontinental Ltd's latest Q4 FY26 results are concerning, showing a net profit of -₹0.65 crores and a negative PAT margin of -10.45%, despite a 6.29% increase in net sales. Overall, the company continues to face significant operational and financial challenges, indicating that the results are more bad than good.

Medico Intercontinental Ltd's latest results for Q4 FY26 indicate a troubling financial situation. The company reported a consolidated net profit of -₹0.65 crores, which reflects a significant decline of 155.56% year-on-year. This marks the continuation of a challenging fiscal year, with losses in all quarters.<BR><BR>On the positive side, net sales increased by 6.29% year-on-year to ₹22.49 crores, the highest quarterly figure recorded. However, this revenue growth is overshadowed by severe operational inefficiencies and a negative PAT margin of -10.45%, compared to a positive margin of 5.43% in the same quarter last year. <BR><BR>The company's return on equity (ROE) has plummeted to just 0.02%, indicating a lack of profitability and efficiency in generating returns for shareholders. Additionally, the interest costs surged dramatically, leading to a profit before tax of -₹1.55 crores, a stark contrast to the profit reported in the previous year.<BR><BR>Overall, while there was some sequential improvement in sales, the underlying financial health of Medico Intercontinental is concerning, characterized by persistent losses, high leverage, and deteriorating margins. This paints a picture of a company facing significant operational and financial challenges, suggesting that the latest results are more bad than good.

Should I buy, sell or hold Medico Intercontinental Ltd?

When is the next results date for Medico Intercontinental Ltd?

The next results date for Medico Intercontinental Ltd is 22 May 2026.

The next results date for Medico Intercontinental Ltd is scheduled for 22 May 2026.

Is Medico Intercon. overvalued or undervalued?

As of November 17, 2025, Medico Intercon. is considered very expensive with a PE ratio of 3266.00, significantly higher than its peers, and has underperformed the market with a year-to-date return of -40.18%.

As of 17 November 2025, the valuation grade for Medico Intercon. has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, with a staggering PE ratio of 3266.00, an EV to EBIT of 93.80, and an EV to EBITDA of 25.08. These ratios suggest that the stock is priced excessively high relative to its earnings and operational performance.<BR><BR>In comparison to its peers, Medico Intercon. stands out with a PE ratio that is dramatically higher than Bajaj Finance at 34.85 and Life Insurance at 11.33, both of which are in the same industry. Additionally, the company's ROCE of 0.60% and ROE of 0.02% further highlight its inefficiency in generating returns relative to its equity. Recent stock performance has also been poor, with a year-to-date return of -40.18%, contrasting sharply with the Sensex's return of 8.72%, reinforcing the notion that Medico Intercon. is currently overvalued.

How has been the historical performance of Medico Intercon.?

Medico Intercon has shown significant growth in net sales and profitability, with net sales increasing from 10.30 Cr in Mar'19 to 95.32 Cr in Mar'25, and profit after tax rising from 0.74 Cr to 4.96 Cr. However, the company faced cash flow challenges in the latest fiscal year, reporting a negative cash flow of -7.00 Cr in Mar'25.

Answer:<BR>The historical performance of Medico Intercon shows a significant growth trajectory in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Medico Intercon's net sales have increased from 10.30 Cr in Mar'19 to 95.32 Cr in Mar'25, indicating a robust growth trend. Total operating income followed a similar pattern, rising from 10.30 Cr in Mar'19 to 95.32 Cr in Mar'25. The company's total expenditure, excluding depreciation, also grew from 9.30 Cr in Mar'19 to 87.13 Cr in Mar'25, reflecting increased operational costs alongside sales growth. Operating profit (PBDIT) has shown a consistent upward trend, climbing from 1.01 Cr in Mar'19 to 8.61 Cr in Mar'25, while profit before tax rose from 1.00 Cr to 6.82 Cr in the same period. The profit after tax has similarly improved, reaching 4.96 Cr in Mar'25 from 0.74 Cr in Mar'19. The company's total assets increased from 36.04 Cr in Mar'20 to 75.76 Cr in Mar'25, while total liabilities also rose, reflecting a growth in debt from 4.85 Cr to 16.92 Cr. Cash flow from operating activities has fluctuated, with a negative cash flow of -7.00 Cr in Mar'25, contrasting with positive cash flows in previous years. Overall, Medico Intercon has demonstrated significant growth in sales and profitability, although it has faced challenges in cash flow management in the latest fiscal year.

How big is Medico Intercon.?

As of 24th July, Medico Intercontinental Ltd has a market capitalization of 39.00 Cr, with recent Net Sales of 96.01 Cr and a Net Profit of 5.05 Cr. The company's Shareholder's Funds are 45.03 Cr and Total Assets are 56.04 Cr as of March 2024.

As of 24th July, Medico Intercontinental Ltd has a market capitalization of 39.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 96.01 Cr and a Net Profit of 5.05 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 45.03 Cr and Total Assets of 56.04 Cr.

What does Medico Intercon. do?

Medico Intercontinental Ltd, incorporated in 1984, trades pharmaceutical products and operates as a Micro Cap company with recent net sales of 214 Cr and a net profit of 12 Cr as of March 2025. The company has a market cap of INR 39 Cr and key financial metrics include a P/E of 8.00 and a return on equity of 10.38%.

Overview: <BR>Medico Intercontinental Ltd is involved in the trading of pharmaceutical products and operates within the Trading & Distributors industry, categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated on August 14, 1984, in Ahmedabad, India, and changed its name to "Medico Intercontinental Limited" in December 2018. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 214 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 12 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 39 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.35 <BR>Return on Equity: 10.38% <BR>Price to Book: 0.80 <BR><BR>Contact Details: <BR>Address: 213 2nd Floor, Raheja Chambers Nariman Point Mumbai Maharashtra : 400021 <BR>Email: mail@medicointercontinental.com <BR>Website: http://www.medicointercontinental.com

Who are the top shareholders of the Medico Intercon.?

The top shareholder of Medico Intercon is Shah Samir, holding 44.43% of shares, with no pledged promoter holdings. Individual investors own 39.51%, and the highest public shareholder is Lalita at 1.5%.

The top shareholders of Medico Intercon are primarily the promoters, with Shah Samir holding the largest share at 44.43%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Lalita, who owns 1.5%. Additionally, individual investors collectively hold 39.51% of the company's shares.

Why is Medico Intercon. falling/rising?

As of 10-Jun, Medico Intercontinental Ltd's stock price is Rs 40.75, down 2.98%, underperforming its sector. Despite positive financial results, weak long-term fundamentals and bearish technical indicators contribute to its decline.

As of 10-Jun, Medico Intercontinental Ltd's stock price is currently at Rs 40.75, reflecting a decrease of Rs 1.25 or 2.98%. Today's price summary indicates that the stock has underperformed its sector by 2.65%, with an intraday low of Rs 40.16, marking a decline of 4.38%. The stock has shown mixed performance over various periods, with a 1-month return of +12.91% but a year-to-date decline of -25.37%. Despite positive financial results, including a 35.49% growth in PAT and a 35.36% increase in net sales over the latest six months, the stock's weak long-term fundamental strength and bearish technical indicators contribute to its current downward movement.<BR><BR>In the broader market context, the Sensex has gained 2.05% over the past week, contrasting with Medico's slight decline of -0.10% during the same period. This underperformance is further highlighted by the stock's negative returns over the past year and its inability to keep pace with the BSE 500 index in the long term. While the stock is trading at a fair value compared to its peers, the falling investor participation and the bearish technical outlook suggest that market sentiment remains cautious, leading to the stock's current decline.

What is the technical trend for Medico Intercon.?

As of June 5, 2025, Medico Intercon's trend is mildly bearish, with daily moving averages indicating bearishness, while weekly indicators show mild bullishness, but overall mixed signals suggest a lack of strong momentum.

As of 5 June 2025, the technical trend for Medico Intercon has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook, while the weekly MACD and KST show a mildly bullish trend. However, the monthly MACD and KST remain bearish, suggesting underlying weakness. The Bollinger Bands on a monthly basis are mildly bearish, further supporting this cautious view. Overall, the mixed signals across different time frames indicate a lack of strong momentum, reinforcing the mildly bearish stance.

Who are in the management team of Medico Intercon.?

As of March 2023, the management team of Medico Intercon includes Samir Shah (Managing Director), Tanvi Shah (Chairperson), Swati Vikramkumar Shah (Director), Funeeta Sharma (Company Secretary), and several independent directors, with Samir Shah being the only one receiving remuneration (Rs. 24.0 lacs).

As of March 2023, the management team of Medico Intercon includes the following individuals:<BR><BR>1. Samir Shah - Managing Director (Remuneration: Rs. 24.0 lacs)<BR>2. Tanvi Shah - Chairperson (Remuneration: Rs. 0)<BR>3. Swati Vikramkumar Shah - Director (Remuneration: Rs. 0)<BR>4. Funeeta Sharma - Company Secretary & Compliance Officer (Remuneration: Rs. 0)<BR>5. Ankur Amiram Dave - Independent Director (Remuneration: Rs. 0)<BR>6. Nikul Dipakbhai Shah - Independent Director (Remuneration: Rs. 0)<BR>7. Priyank Lalitbhai Sancheti - Additional Independent Director (Remuneration: Rs. 0)<BR><BR>This team comprises a mix of executive and independent directors, with Samir Shah serving as the Managing Director.

Has Medico Intercon. declared dividend?

Medico Intercontinental Ltd has declared a 1% dividend, amounting to 0.1 per share, with an ex-date of June 23, 2023. Total returns have varied significantly, showing negative returns in the short term but positive returns over the longer term, particularly a 154.34% total return over five years.

Medico Intercontinental Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.1<BR>- Ex-date: 23 Jun 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -24.43%, the dividend return was 0%, resulting in a total return of -24.43%.<BR><BR>For the 1-year period, the price return was -5.09%, the dividend return was 0%, leading to a total return of -5.09%.<BR><BR>Over the 2-year period, the price return was -44.33%, the dividend return was 0.14%, culminating in a total return of -44.19%.<BR><BR>In the 3-year period, the price return was 50.18%, the dividend return was 0.37%, which resulted in a total return of 50.55%.<BR><BR>For the 4-year period, the price return was -0.12%, the dividend return was 0.24%, yielding a total return of 0.12%.<BR><BR>In the 5-year period, the price return was 153.8%, the dividend return was 0.54%, leading to a total return of 154.34%.<BR><BR>Overall, while Medico Intercontinental Ltd has declared a dividend, the total returns over various periods show significant fluctuations, with negative returns in the short term and positive returns over the longer term, particularly in the 5-year period.

Who are the peers of the Medico Intercon.?

Medico Intercon.'s peers include Redington, MMTC, MSTC, Ravindra Energy, Tavernier Res., Quasar India, Salora Intl., Fortune Interntl, and Lesha Industries. Redington shows excellent management and growth, while Medico Intercon. has average management risk and below-average growth, with a 1-year return of -7.97%.

Peers: The peers of Medico Intercon. are Redington, MMTC, MSTC, Ravindra Energy, Tavernier Res., Quasar India, Salora Intl., Fortune Interntl, and Lesha Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Redington, while Average management risk is found at MMTC, MSTC, and Medico Intercon. Below Average management risk is present at Ravindra Energy, Tavernier Res., Quasar India, Salora Intl., and Lesha Industries, and the rest. Growth is Excellent at Redington, Average at MMTC and MSTC, and Below Average at Medico Intercon., Ravindra Energy, Tavernier Res., Quasar India, Salora Intl., and Lesha Industries, and the rest. Capital Structure is Excellent at Medico Intercon., Good at Lesha Industries, and Good at Redington, while Below Average is seen at MMTC, MSTC, Ravindra Energy, Tavernier Res., Quasar India, Salora Intl., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ravindra Energy at 142.31%, while the lowest is Lesha Industries at -56.48%. Medico Intercon.'s 1-year return is -7.97%, which is higher than Lesha Industries but lower than Ravindra Energy. Additionally, MSTC, Ravindra Energy, Tavernier Res., Quasar India, Salora Intl., Fortune Interntl, and Lesha Industries all have negative six-month returns.